本帖最后由 老马 于 2012-1-13 21:20 编辑
. `8 ? f+ X7 O5 M7 P& a% {
- ]0 { G: \0 g; a9 ?( q$ u* @爱必妥和阿瓦斯丁的比较9 l0 ^+ D" Z0 [) H6 U1 K
/ V. Q$ Y* }$ G
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/1 E* m J$ a" }1 c- `/ x
; s5 X! f1 K/ l! z E
- a C! y/ n- F- q3 _6 x; S1 {
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
- H; z3 g9 y3 `% ?==================================================% v+ @! w0 O% S- b+ i
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
+ j- j- H; D" M2 RPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
: r6 w5 `' f+ D4 g- F6 HResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
# G; _" V9 f" b6 i x3 Z5 P7 H( f( v
|